Intermediate-term evaluation of a pratical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*

Hemoglobin

Volumn 35, Issue 3, 2011, Pages 199-205

  Ha, Shau Yin ^a   Mok, Amanda Sio Peng ^a   Chu, Winnie Chiu Wing ^b   Rasalkar, Darshana Dattatray ^b   Cheuk, Daniel Ka Leung ^a   Chiang, Alan Kwok Shing ^a   Ho, Marco Hok Kung ^a   Chan, Godfrey Chi Fung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cardiac magnetic resonance imaging T2* (MRI T2*); Chelation protocol; Combined therapy; Deferiprone (L1); Deferoxamine(DFO); Serum ferritin(SF); Thalassemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON;

ADOLESCENT; ADULT; AGRANULOCYTOSIS; CHELATION THERAPY; CHILD; CLINICAL PROTOCOL; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DOSE INCREASE; EVALUATION; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IRON CHELATION; IRON OVERLOAD; LONGITUDINAL STUDY; MALE; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCHOOL CHILD; SCHOOL CHILD; THALASSEMIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CHELATION THERAPY; CHILD; CHILD, PRESCHOOL; DEFEROXAMINE; FEMALE; FERRITINS; FOLLOW-UP STUDIES; HEART DISEASES; HUMANS; IRON CHELATING AGENTS; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MYOCARDIUM; PATIENT SELECTION; PYRIDONES; RISK ASSESSMENT; STROKE VOLUME; YOUNG ADULT;

EID: 79957467894     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630269.2011.579007     Document Type: Conference Paper

References (8)

1. Pennell DJ. T2* Magnetic resonance and myocardial iron in thalassemia. Ann NY Acad Sci. 2005;1054: 373-378 (Pubitemid 43031044)
2. Ha SY, Mok AS, Chu WC, et al. A practical chelation protocol based on stratification of thalassemicpatientsby serum ferritinand magnetic resonance imaging cardiacT2*.Hemoglobin. 2009;33(5): 323-331
3. Telfer PT, Prescott E, Holden S, et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br JHaematol. 2000;110(4): 971-977
4. Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identificationof effective chelation therapy protocols.Hemoglobin. 2008;32(1-2): 41-47 (Pubitemid 351264511)
5. TannerMA, Galanello R, Dessi C, et al.Combined chelation therapyinthalassemia major forthe treatmentof severemyocardial siderosiswithleftventricular dysfunction.JCardiovasc Magn Reson. 2008;10(1): 12
6. TsironiM,AssimakopoulosG, PolonofiK, RigakiK, AessoposA.Effectsof combined deferiprone anddeferoxamine chelation therapyoniron loadindicesin β-thalassemia. Hemoglobin. 2008;32 (1-2): 29-34 (Pubitemid 351264515)
7. Kolnagou A, Kleanthous M, Kontoghiorghes GJ. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/ deferoxamine combination and their maintenance thereafterbydeferiprone monotherapy. EurJHaematol. 2010;85(5): 430-438
8. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.BrJHaematol. 2010;148(3): 466-475